An experimental weight-loss drug cut knee pain by at least half in roughly two-thirds of patients with osteoarthritis, according to combined results from two large phase 3 trials published Nov. 8 in the New England Journal of Medicine.
Participants receiving the highest dose of retatrutide lost an average of about 25% of their body weight over the course of the studies, which enrolled more than 1,000 people in total and were led by Northwestern University. In the placebo group, 38% reported a similar level of pain relief, ScienceDaily reported.
Retatrutide, developed by Eli Lilly, is a once-weekly injectable “triple agonist” that activates receptors for three hormones — GLP-1, GIP and glucagon — unlike earlier drugs such as semaglutide and tirzepatide that act on one or two pathways, Medical News Today reported. In the trials, higher doses produced weight loss of roughly 20% to 25%. Participants also saw reductions in blood pressure, blood lipid levels and markers of inflammation.
The two trials, TRIUMPH-4 and TRIUMPH-1-OA, used the Western Ontario and McMaster Universities Arthritis Index (WOMAC) to measure pain. In TRIUMPH-4, which ran for 68 weeks, pain scores for people on retatrutide decreased by 3.96 (9 mg) and 3.74 (12 mg) on a 0-to-10 scale, compared with a 2.12 reduction with placebo.
Those on the drug lost around one-fifth of their body weight, while the placebo group lost just under 5%. In TRIUMPH-1-OA, which ran for 80 weeks, pain scores fell by 3.22 (4 mg), 3.48 (9 mg) and 3.64 (12 mg), versus 1.87 for placebo, according to Medical News Today.
Philip Conaghan, a study co-author and professor of musculoskeletal medicine at the University of Leeds, presented TRIUMPH-4 results Nov. 8 at the American College of Rheumatology annual meeting in Orlando, Florida. TRIUMPH-1-OA findings were scheduled for a poster session the same day.
“Participants had remarkable responses,” Schnitzer said.
Schnitzer emphasized that lifestyle changes should remain the starting point for people who are overweight. Diet, exercise and other sustainable adjustments can reduce symptoms without the cost of a new drug and avoid some side effects seen with GLP-1 treatments, including gastrointestinal problems and muscle loss.
That muscle issue matters for knee osteoarthritis patients because the muscles around the joint help stabilize it; losing too much muscle can make mobility even harder, Enmnews reported.
People who already needed a knee replacement were excluded from the trials.

Painful knee osteoarthritis affects about 5% of Americans, or roughly 15 million people. Previous studies have shown that losing 5% to 10% of body weight through diet and exercise can improve symptoms, but losing more than 10% through those approaches alone is often challenging, especially when knee pain makes movement harder.